ARTICLE | Emerging Company Profile
Solu’s CyTaCs bring antibody pharmacology to small molecule targets
With tech from GSK and a $31 million seed round, the company aims to enter the clinic within two years
August 2, 2023 10:30 PM UTC
Solu is using the induced proximity logic popularized by targeted degraders to trigger antibody-dependent killing of pathogenic cells driving cancer, inflammation and autoimmune diseases. Having licensed an industrialized platform and an arsenal of preclinical candidates from GSK, the newco thinks its first program will reach the clinic within two years.
Solu Therapeutics Inc. announced a $31 million seed round on Aug. 1 co-led by Longwood Fund and Santé Ventures, with participation from DCVC Bio, Astellas Venture Management and Alexandria Venture Investments...